Hinova Self-developed Prostate Cancer Drug HC-1119 Enters Global Multicentered Phase III clinical trial
HC-1119, a novel molecular entity, is a small molecule AR antagonist developed by Hinova for the treatment of advanced prostate cancer. In 2016, its Phase I clinical trial was approved by the National Medical Products Administration (NMPA) and has completed by now. An IND application was submitted to the U.S. in January 2019 and was approved for direct entry into Phase III clinical studies in February of the same year. Global multicentered Phase III trials of HC-1119 are currently underway in the United States, China, the European Union, Australia, Canada, Russia, etc.
About Hinova
Hinova is an international and clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases. Hinova has committed to the discovery and development of innovative medicines for patients globally through deuteration and targeted protein degradation technologies.
- Hinova's Clinical Trial Application for the Combination of HP501 Sustained-release Tablets and xanthine oxidase inhibitors in the Treatment of Hyperuricemia/Gout was Accepted by NMPA
- Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
- Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
- Hinova Announces Phase III Clinical Trial of Deutenzalutamide (HC-1119) in Chinese Patients with castration-resistant prostate cancer (mCRPC) Met Primary Endpoint
- Hinova Today Listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange (SSE) in China, Relying on PROTAC and Deuterium Technology to Develop Innovative D
